In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Deal Gives Lundbeck US Foothold

Executive Summary

Lundbeck's $270 million deal with Merck & Co. to develop and commercialize the Phase III gaboxadol for sleep disorders in the US finally gives the Danish CNS specialist a foothold in the US market. Gaboxadol provides Merck an entry into the burgeoning insomnia market and the deal-the company's largest-ever single-product pact-is indicative of the Big Pharma's growing flexibility and acceptance of external research.
Advertisement

Related Content

Lilly Doubles Down on Insomnia with Hypnion Acquisition
Insomnia: Pharma Wakes Up to the Next Huge CNS Market
Pierre Fabre: Time to Reap R&D Rewards In-House
Lundbeck: Cipralex Falters in Europe
Lundbeck: Cipralex Falters in Europe
Merck Opens Up to Europe
Merck's Vaccines: Why the Company's Down, but Definitely Not Out
Sepracor's Primary Care Ambitions
The Infrastructure Dilemma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel